You are here: Industry Insights > CGRP

News List

Allergan scores year-end CGRP nod for migraine med Ubrelvy fiercepharma
December 31, 2019
The CGRP migraine prevention field already has three meds from Amgen, Eli Lilly and Teva vying for market share, and now Allergan has scored the first approval for an oral CGRP to treat migraines as they happen.
Biohaven, sporting new data, moves closer to CGRP finish line—and maybe M&A fiercepharma
July 13, 2019
Aiming to break into a three-way battle among large drugmakers in the brand-new CGRP migraine class, tiny Biohaven Pharmaceutical has released detailed data for its own candidate, which one group of analysts figures could reach blockbuster status.
First treatment for cluster headaches approved in US europeanpharmaceuticalreview
June 10, 2019
The FDA has given its approval to a new injection for cluster headaches which reduce frequency of attacks.
Teva scraps development of CGRP inhibitor Ajovy in cluster headaches firstwordpharma
April 24, 2019
Teva said Tuesday that it will end development of Ajovy (fremanezumab) in cluster headaches after a pre-specified futility analysis of a Phase III study in episodic cluster headache revealed that the trial’s primary endpoint is unlikely to be met.
Allergan files anti-CGRP migraine drug in the US pharmatimes
March 12, 2019
US regulators have accepted for review Allergan’s application to market ubrogepant for the acute treatment of migraine.
Biohaven Reaches Targeted Therapeutic Exposures of BHV-3500 americanpharmaceuticalreview
February 19, 2019
Biohaven announced that administration of intranasal BHV-3500 in a Phase 1 clinical trial has achieved targeted therapeutic exposures and that the compound will advance into a Phase 2 trial to evaluate efficacy for the acute treatment of migraine....
Don't fret about Lilly's 3rd-to-market start in CGRP, executive says. fiercepharma
January 10, 2019
Eli Lilly's Emgality didn't take the first-to-market crown in the budding CGRP field of migraine prevention drugs. It didn't even come in second.
Biohaven Announces Positive Results from Rimegepant Safety Study americanpharmaceuticalreview
December 11, 2018
Biohaven announced initial positive results from its ongoing long-term, open-label safety study of its oral calcitonin gene-related peptide (CGRP) receptor antagonist, rimegepant.....
Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis ODT americanpharmaceuticalreview
December 04, 2018
Biohaven announced positive topline results from a randomized, controlled Phase 3 clinical trial (BHV3000-303 or Study 303) evaluating the efficacy ......
Lilly’s Emgality wins first nod for migraine prevention pharmatimes
September 29, 2018
The US Food and Drug Administration have green-lighted use of Eli Lilly’s non-opioid pain drug Emgality for the prevention of migraine.

Previous page 1 2 Next page